(Alliance News) - Advanced Oncotherapy PLC on Friday said it has demonstrated the potential capability and superiority of Light in "biologically enhanced particle therapy" to treat resistant cancers.
The AIM-listed developer of next-generation proton therapy systems for cancer treatment said its findings build on research at the Mayo Clinic, which demonstrated the benefits of combining proton therapy with targeted small molecule damage repair inhibitors.
"Our Light system, due to its smaller beam size compared to legacy systems and its ability to deposit a greater level of radiation damage in a micro-target volume, is ideally suited to further contribute to the development of personalised medicines," noted Chief Clinical Officer Jonathan Farr.
Advanced Oncotherapy shares were trading 1.6% higher in London on Friday at 39.10 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Advanced Oncotherapy (AVO)